NIH RePORTER
Cure8 regulatory brief
Why This Matters
This project aims to develop a new anti-inflammatory therapy targeting TREM-1 on macrophages, a pathway implicated in IBD. If successful, the approach could offer an alternative for patients who do not respond to current biologics.
Who Should Pay Attention
Researchers working on IBD immunology or macrophage-targeted therapies; clinicians and patients interested in emerging treatment mechanisms; patients who have inadequate response or intolerance to existing biologics.
Study Snapshot
Story typeRegulatory
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This is an NIH Reporter project record describing funded preclinical Phase I work to develop ligand-independent TREM-1 inhibitory peptides (GF9 and GA31-LPC) as a potential therapy for IBD. The project will generate and characterize the peptides in vitro and test them in two mouse colitis models (DSS and adoptive T cell transfer).
Endpoints listed include colitis score, weight, stool blood/diarrhea, histology, colon metrics and cytokine assays. The record frames this as Phase I (preclinical) work with possible follow-on IND-enabling studies if results support advancement.
The entry summarizes prior animal data for these peptides in other inflammatory models and states that the team will compare their compounds to LR12. This is a research/project page (not a clinical trial report or human study result), so it describes planned experiments rather than clinical outcomes. It does not provide human safety or efficacy data.
Keep In Mind
This is a funded preclinical project-record describing planned laboratory and mouse-model experiments (Phase I stage in the project's framing). It does not report clinical trial results or human data; further IND-enabling work and formal human trials would be required to evaluate safety and efficacy in people.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsAlexander B Sigalov
InstitutionSIGNABLOK, INC.
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedSep 4, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - R43DK148026 - $353,264
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Engineered perturbations to define B cell entry, competition, and function in intestinal immunity and inflammation
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...
Production of low-cost heat stable forms of adalimumab in maize for treatment of inflammatory bowel disease.
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
Mobius Care Receives Funding from Crohn's & Colitis Foundation
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...